（文章来源：每日经济新闻） 每经AI快讯，诚意药业（603811.SH）1月16日在投资者互动平台表示，公司原料药有直接向欧盟出口 的业务，近年来出口欧盟营收占公司整体营收比例较小。 ...

Core Viewpoint - The company expects a significant net loss for the fiscal year 2025, with projections ranging from -75 million to -58 million yuan, indicating a year-on-year decline of 110.21% to 171.83% [1] Financial Performance - The anticipated net profit, excluding non-recurring gains and losses, is projected to be between -76 million and -59 million yuan, reflecting a year-on-year decrease of 109.10% to 169.34% [1] - The expected loss for the reporting period is between 58 million and 75 million yuan, with a decline in gross margin compared to the same period last year [1] Operational Challenges - The decline in performance is attributed to slight decreases in market prices for certain products, incomplete capacity release from newly established projects, and higher unit product costs [1] - The introduction of new products in 2025 has led to increased initial production costs [1] Strategic Focus - The company maintains a strategic focus on "innovation-driven development," increasing investment in new product research and development, enhancing the R&D management system, and deepening industry-academia-research collaboration, which has resulted in higher R&D expenses [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 4.07 | -17.94% | 249.58万 | 10.28亿 | | 688690 | 纳微科技 | 27.09 | -8.29% | 21.97万 | 6.07亿 | | 300452 | 山河药辅 | 15.54 | -7.77% | 50.00万 | 7.80亿 | | 300267 | 尔康制药 | 3.96 | -4.58% | 134.65万 | 5.38亿 | | 300016 | 北陆药业 | 9.21 | -4.56% | 39.32万 | 3.68亿 | | 688117 | 圣诺生物 | 42.64 | -4.07% | 9.03万 | 3.92亿 | | 300204 | 舒泰神 | 28.52 | -3.19% | 20.54万 | 5.89亿 | | 300254 | 仟源医药 | 10.93 | -3.10% | 18.30万 | 2.01亿 | | 301301 | 川宁生物 | ...

津药药业（600488.SH）1月16日在投资者互动平台表示，公司在欧盟地区的原料药业务覆盖多个主要 欧盟国家，外销业务主要由控股子公司天发药业进出口有限公司负责。目前，公司该区域业务年营业收 入在公司整体营业收入中占比较小。未来，公司将持续关注海外市场机遇，结合自身业务发展规划与市 场需求，加强产品海外注册、拓展海外业务，增强企业全球竞争力。 每经AI快讯，有投资者在投资者互动平台提问：请问公司近年是否存在向欧盟出口或销售的相关业 务？如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售 主要通过哪种方式实现？是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进 行销售，或通过第三方贸易商、代理商转销至欧盟市场？ （文章来源：每日经济新闻） ...

每经AI快讯，1月16日，联环药业(600513.SH)公告称，公司于近日收到国家药监局核准签发的关于2类 改良新药LH-2417片的《药物临床试验批准通知书》，并将于近期开展临床试验。该药品用于前列腺肥 大的男性良性前列腺增生的体征和症状的初始治疗。截至公告披露日，公司累计研发投入约为136.78万 元。由于改良新药的前期研发以及产品从研制到投产的周期长，容易受到不确定因素影响，预计短期内 不会对公司营业收入和经营业绩产生重大影响。 （文章来源：每日经济新闻） ...

Group 1 - Eddie Pharmaceuticals' stock price increased by 5.15% on January 16, reaching 22.06 CNY per share, with a trading volume of 520 million CNY and a turnover rate of 6.05%, resulting in a total market capitalization of 9.282 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 24.14% during this period [1] - The company, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived proteins 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceuticals, the Xingsheng Global Fund has a fund that entered the top ten in the third quarter, holding 6.229 million shares, which accounts for 1.48% of the circulating shares [2] - The estimated floating profit for today is approximately 6.7273 million CNY, with a total floating profit of 25.4142 million CNY during the three-day increase [2] - The Xingsheng Global Fund's mixed fund (LOF) A (163415) was established on December 18, 2012, with a latest scale of 14.567 billion CNY, yielding 6.54% this year, ranking 2504 out of 8847 in its category, and 48.84% over the past year, ranking 2241 out of 8094 [2]

Core Viewpoint - Heng Rui Medicine's stock price has shown fluctuations, with a recent decline of 2.01% and a year-to-date increase of 3.91% [1][2]. Company Overview - Heng Rui Medicine, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, addressing various diseases such as autoimmune, metabolic, cardiovascular, infectious, respiratory, hematological, pain management, neurological, ophthalmic, and renal diseases [2]. - The main revenue sources are 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2]. Financial Performance - For the period from January to September 2025, Heng Rui Medicine achieved a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit attributable to shareholders of 5.751 billion yuan, with a year-on-year increase of 24.50% [3]. - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed in the last three years [4]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 397,300, with an average of 16,058 circulating shares per person, a decrease of 8.21% from the previous period [3]. - Major shareholders include Hong Kong Central Clearing Limited, holding 487 million shares, and China Securities Finance Corporation, holding 95.4 million shares, with some reductions in holdings noted [4].

Core Viewpoint - XinNuoWei (300765) is expected to report a significant net profit loss for the year 2025, indicating a substantial decline compared to the previous year [1] Financial Performance - The company anticipates a net profit loss ranging from 170 million to 255 million yuan for 2025, representing a year-on-year decline of 416% to 575% [1] - Excluding non-recurring gains and losses, the expected net profit loss is projected to be between 210 million and 315 million yuan, reflecting a year-on-year decrease of 596% to 844% [1]

Group 1 - Garden Biologics experienced a stock price increase of 3.57% on January 15, with a trading volume of 828 million yuan [1] - The company had a net financing buy of -2.61 million yuan on the same day, with a total financing and margin balance of 732 million yuan [1] - The financing balance of Garden Biologics is 730 million yuan, accounting for 8.13% of its circulating market value, which is above the 80th percentile level over the past year [1] Group 2 - As of December 31, the number of shareholders for Garden Biologics was 26,200, a decrease of 12.35% from the previous period [2] - For the period from January to September 2025, the company reported a revenue of 936 million yuan, a year-on-year decrease of 0.20%, and a net profit attributable to shareholders of 234 million yuan, down 3.07% year-on-year [2] - The company has distributed a total of 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed in the last three years [2]

Group 1 - Two A-shares are set for equity registration today, with both companies planning to distribute dividends [1] - The dividend registration date for the two stocks is January 16, with Vision Intelligence and Aladdin offering the highest dividends of 3.00 yuan and 0.70 yuan per 10 shares, respectively [1] - Additionally, three other stocks have announced dividend distribution plans, with Life Pharmaceutical and Tianshan Aluminum proposing the highest dividends of 3.0 yuan and 1.0 yuan per 10 shares, respectively [1]